Parenteral augmentin: pharmacokinetics.
The pharmacokinetics of intravenous Augmentin have been investigated and the data found to fit a two compartment model. In the first study, to a crossover design, a bolus injection of 1.2 g Augmentin was given to 8 healthy volunteers with and without probenecid. It was found that the serum concentrations of amoxycillin were increased in the presence of probenecid, but those of clavulanic acid were unaffected. In a second study a further 8 volunteers received an infusion over 30 min of 2.2 g Augmentin. At the end of the infusion, peak concentrations in excess of 100 micrograms/ml were recorded for amoxycillin and 14 micrograms/ml for clavulanic acid. In both studies the serum and urinary concentrations of amoxycillin and clavulanic acid obtained were well above those considered necessary to achieve a therapeutic effect.
D000328:Adult; D000658:Amoxicillin / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism* / Q000494:pharmacology / Q000652:urine; D019980:Amoxicillin-Potassium Clavulanate Combination; D019818:Clavulanic Acid; D002969:Clavulanic Acids / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism* / Q000494:pharmacology / Q000652:urine; D004338:Drug Combinations; D005260:Female; D006207:Half-Life; D006801:Humans; D007004:Hypoglycemic Agents / Q000378:metabolism*; D007263:Infusions, Parenteral; D007275:Injections, Intravenous; D007700:Kinetics; D008297:Male; D011339:Probenecid / Q000494:pharmacology
D002969:Clavulanic Acids; D004338:Drug Combinations; D007004:Hypoglycemic Agents; D019818:Clavulanic Acid; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin; D011339:Probenecid